Richard D Kennedy
Overview
Explore the profile of Richard D Kennedy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
2481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hanna C, Dunne V, Walker S, Butterworth K, McCabe N, Waugh D, et al.
Cancers (Basel)
. 2021 Jan;
13(1).
PMID: 33396656
Radical radiotherapy, often in combination with hormone ablation, is a safe and effective treatment option for localised or locally-advanced prostate cancer. However, up to 30% of patients with locally advanced...
12.
Malla S, Fisher D, Domingo E, Blake A, Hassanieh S, Redmond K, et al.
Clin Cancer Res
. 2020 Oct;
27(1):288-300.
PMID: 33028592
Purpose: The DNA damage immune response (DDIR) assay was developed in breast cancer based on biology associated with deficiencies in homologous recombination and Fanconi anemia pathways. A positive DDIR call...
13.
Sharma P, Barlow W, Godwin A, Parkes E, Knight L, Walker S, et al.
J Clin Oncol
. 2019 Oct;
37(36):3484-3492.
PMID: 31657982
Purpose: To independently validate two biomarkers, a 44-gene DNA damage immune response (DDIR) signature and stromal tumor-infiltrating lymphocytes (sTILs), as prognostic markers in patients with triple-negative breast cancer (TNBC) treated...
14.
Beirne J, McArt D, Roddy A, McDermott C, Ferris J, Buckley N, et al.
Gynecol Oncol
. 2019 Sep;
155(2):305-317.
PMID: 31493898
Objective: High grade serous carcinoma (HGSC) is the most common and most aggressive, subtype of epithelial ovarian cancer. It presents as advanced stage disease with poor prognosis. Recent pathological evidence...
15.
Wilkinson R, Burden R, McDowell S, McArt D, McQuaid S, Bingham V, et al.
J Oncol
. 2019 Jul;
2019:3980273.
PMID: 31346333
Cathepsin S (CTSS) has previously been implicated in a number of cancer types, where it is associated with poor clinical features and outcome. To date, patient outcome in breast cancer...
16.
Gilmore E, McCabe N, Kennedy R, Parkes E
J Oncol
. 2019 Jul;
2019:4325105.
PMID: 31320901
Historically the development of anticancer treatments has been focused on their effect on tumor cells alone. However, newer treatments have shifted attention to targets on immune cells, resulting in dramatic...
17.
Cox O, Edmunds S, Simon-Keller K, Li B, Moran B, Buckley N, et al.
Cancer Res
. 2019 Mar;
79(10):2619-2633.
PMID: 30885980
The PDLIM2 protein regulates stability of transcription factors including NF-κB and STATs in epithelial and hemopoietic cells. PDLIM2 is strongly expressed in certain cancer cell lines that exhibit an epithelial-to-mesenchymal...
18.
Turkington R, Knight L, Blayney J, Secrier M, Douglas R, Parkes E, et al.
Gut
. 2019 Mar;
68(11):1918-1927.
PMID: 30852560
Objective: Current strategies to guide selection of neoadjuvant therapy in oesophageal adenocarcinoma (OAC) are inadequate. We assessed the ability of a DNA damage immune response (DDIR) assay to predict response...
19.
Humphries M, Hynes S, Bingham V, Cougot D, James J, Patel-Socha F, et al.
J Oncol
. 2019 Jan;
2018:2937012.
PMID: 30651729
The role of PD-L1 as a prognostic and predictive biomarker is an area of great interest. However, there is a lack of consensus on how to deliver PD-L1 as a...
20.
Blackburn N, Mc Veigh J, Mc Caughan E, Kennedy R, McIntosh S, Wilson I
PLoS One
. 2018 Aug;
13(8):e0202859.
PMID: 30153282
Introduction: Current evidence suggests that patients who have latissimus dorsi (LD) breast reconstruction following mastectomy for breast cancer can experience long-term shoulder dysfunction. However, as there is no standardised assessment...